Drugs tsara don karya da kuma sassauta ƙuduri a COPD
Daya daga cikin mahimman siffofi na cutar cututtuka na al'ada (COPD) ita ce samar da ƙananan ƙwayoyin cuta a cikin huhu. Wannan cigaba, wani lokaci ana kiransa azabar ƙwararruwar ƙwayar cuta, ta haifar da kumburi na tsawon lokaci wanda ya ƙaru duka lambar da girman da ake kira "gwanayen gogettes" wanda ke sanya sassan iska.
Yayinda kwayoyin gwaigula suna amfani da kullun a matsayin nau'i na kariya, tare da COPD aikin samar da kima zai iya ɓoye wurare, ya sa ya fi numfashi.
Ɗaya daga cikin hanyar kawar da wannan ginin shine tare da maganin da ake kira na mucolytic. Ayyukan mucolytics ta hanyar rushe takaddun sunadarai a cikin ɓoye, karya su don haka za su iya samun sauƙi.
Duk da yake ba a dauki nauyin ɓangare na kula da kulawar COPD ba , ka'idodin 2017 da shirin Global Initiative for Disease Lung Disease (GOLD) ya ba da shawara cewa za su iya amfani da su a cikin wadanda basu karɓar ciwon corticosteroids .
Bayani na Mucolytic Drugs a Yin Biyan COPD
Za a iya amfani da mucolytics a cikin wani kwamfutar hannu ko tsari na syrup ko kuma an sanya shi ta hanyar nebulizer . Wasu daga cikin nau'ukan da aka fi amfani da ita a cikin COPD sun haɗa da:
- Carbocysteine
- N-acetylcysteine
- Erdosteine
- Mecysteine
- Guaifenesin
- Bromhexine
Tsarin aikin zai iya bambanta da miyagun ƙwayoyi. Carbocysteine, alal misali, aiki a kan metabolism daga cikin ɗakunan gwanayen kuma yana bayar da antioxidant da anti-inflammatory amfanin.
N-acetylcysteine, ta bambanta, ya rushe shaidu da suke riƙe da ƙulla tare yayin canzawa da rashin daidaituwa da oxidants da antioxidants.
Hanyoyi masu illa na iya bambanta ta hanyar magungunan miyagun kwayoyi da halitta. Muryar magana, tashin zuciya da zawo su ne sakamako mafi rinjaye na tarayya da Allunan, yayin da alamar cutar ta iya haifar da spasms da rashes.
Shirye-shiryen nebulbul zai iya haifar da ciwon makogwaro, tsokar hanci, da kuma fararen fararen launi a bakin ko lebe.
Da yawa kuma, anyi la'akari da ƙwayoyin muƙaman lafiya kuma suna haɗuwa da ƙananan hadarin abubuwan da ke faruwa a cikin mutane tare da COPD. Da wannan aka ce, yana da mahimmancin yin magana da likitanka game da duk wani tasiri, hulda, ko contraindications da ke hade da samfurin mucolytic, ko an tsara ko saya a kan counter.
Amfanin Mucolytics a cikin COPD
Duk da yawan amfani da magungunan mucoactive a COPD, shaidar da ke yanzu ba ta taimaka sosai wajen tasiri.
Binciken da aka yi na 2015 game da gwaje-gwaje na 34 ya ƙaddara cewa wadanda suka dauki nauyin ƙwayoyin cuta ba su da wataƙila za su fuskanci matsalolin COPD . A cikin nazarin sakamakon, duk da haka, wannan an fassara shi zuwa ƙananan rageccen sauƙi na tsawon shekaru uku. Sauran nazarin suna da ƙayyadaddun maɗaukaki da yawa.
Duk da haka, duk da waɗannan rashin kuskuren, wasu sunyi jayayya cewa masu amfani da kwayoyi suna da wurin zama a COPD. Bisa damuwa game da aminci na amfani da corticosteroid na dogon lokaci , akwai shawarwari cewa zasu iya zama masu dacewa a COPD mai ci gaba wanda yanayin hadarin exacerbation ya yi girma ba tare da la'akari da amfani da steroid ba.
Makiyoyi na iya, a cikin waɗannan lokuta, taimakawa wajen rage yawan yawan haɓakawa da kuma bayar da ƙarin cigaba a cikin ingancin rayuwa.
Ɗaya daga cikin magungunan da ke hade da Bronchitis da aka ƙaddara a kan NAC Cost-Utility Study (BRONCUS) ya kara da cewa, idan aka yi amfani da shi tare da cututtukan ƙwayoyin cuta, ƙwayoyin mucolytic za su iya rage yawan halayen COPD da kashi 21 cikin dari.
Hanyoyin ƙaddarawa na iya taimakawa a cikin mutanen da basu da haɗari da corticosteroids ko kuma suna da matsala tare da masu hawan hannu.
Sources:
> Tsarin Duniya na Kwayar Ciwon Kwayoyin Ciki. (2017) Jagora na Pocket zuwa CEDD ganewar asali, Gudanarwa, da Rigakafin: Jagora ga Ma'aikatan Kula da Lafiya (2017 Report) .
> Loukides, S .; Bakakos, P .; da Kostikas, K. "Mucolytics a COPD: Kamar giya jan giya?" PNEUMON. 2013; 4 (26): 1-4.
> Poole, P .; Chong, J; da kuma Cates, J. "Mucolytic jamiái a kan placebo don na kullum bronchitis ko cuta na kullum obstructive cuta." Cochrane Database Syst Rev. 2015; 29: 7: CD001287.